Carnegie Mellon’s commitment to research and technology development creates affordable, accessible and effective healthcare solutions and was the force behind the creation of the Disruptive Health Technology Institute (DHTI) in 2013. Research led by Carnegie Mellon University, is supported by generous funding from Highmark Health. Both organizations are dedicated to working collaboratively to create solutions that will impact large populations, have the ability to provide sub-stantial healthcare savings and lead to improvements in patient safety and quality of life. Catalyzing the Highmark Health investment, the Heinz Endowments supported the establishment of DHTI with a $2 million grant in early 2012. This extraordinary statement of faith in the DHTI concept enabled Carnegie Mellon, Highmark Health, the Allegheny Health Network (AHN) and regional leaders to plan carefully how funds could be best invested to help patients and our region.
The parent company of Highmark Inc., Allegheny Health Network and HM Health Solutions, Highmark Health today leads a national health and wellness enterprise that ranks as America’s third largest integrated healthcare delivery and financing sys-tem. The enterprise employs more than 35,000 people who proudly serve 40 million Americans in all 50 states. As such, Highmark Health is uniquely positioned to under-stand the importance of value-targeted innovation.
Since 2013, DHTI has funded 38 projects led by Carnegie Mellon University (CMU) researchers who are striving to create disruptive solutions. As profiled in this report, the work now under way at DHTI not only represents an investment in our nation’s future wellness, but also embodies a new philosophy for toppling barriers to innova-tive thinking in healthcare technology.